vs

Side-by-side financial comparison of EQUITY BANCSHARES INC (EQBK) and RECURSION PHARMACEUTICALS, INC. (RXRX). Click either name above to swap in a different company.

EQUITY BANCSHARES INC is the larger business by last-quarter revenue ($63.5M vs $35.5M, roughly 1.8× RECURSION PHARMACEUTICALS, INC.). EQUITY BANCSHARES INC runs the higher net margin — 34.8% vs -304.2%, a 339.0% gap on every dollar of revenue. On growth, RECURSION PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (681.7% vs 28.4%). EQUITY BANCSHARES INC produced more free cash flow last quarter ($38.1M vs $-47.3M). Over the past eight quarters, RECURSION PHARMACEUTICALS, INC.'s revenue compounded faster (60.5% CAGR vs 6.6%).

Prosperity Bancshares, Inc. is a bank holding company headquartered in Houston, Texas with operations in Texas and central Oklahoma. As of December 31, 2019, the company operated 285 branches: 65 in the Houston area, including The Woodlands, Texas; 30 in South Texas, including Corpus Christi, Texas and Victoria, Texas; 75 in the Dallas–Fort Worth metroplex; 22 in East Texas; 29 in Central Texas, including Austin, Texas and San Antonio; 34 in West Texas, including Lubbock, Texas, Midland–Odess...

Recursion Pharmaceuticals is a clinical-stage biotechnology company that combines artificial intelligence and large-scale high-throughput biological experimentation to discover and develop innovative therapies for rare diseases, oncology, inflammatory disorders, and other areas of unmet medical need. It primarily operates in North America and partners with global biopharmaceutical firms to advance its robust therapeutic pipeline.

EQBK vs RXRX — Head-to-Head

Bigger by revenue
EQBK
EQBK
1.8× larger
EQBK
$63.5M
$35.5M
RXRX
Growing faster (revenue YoY)
RXRX
RXRX
+653.4% gap
RXRX
681.7%
28.4%
EQBK
Higher net margin
EQBK
EQBK
339.0% more per $
EQBK
34.8%
-304.2%
RXRX
More free cash flow
EQBK
EQBK
$85.4M more FCF
EQBK
$38.1M
$-47.3M
RXRX
Faster 2-yr revenue CAGR
RXRX
RXRX
Annualised
RXRX
60.5%
6.6%
EQBK

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
EQBK
EQBK
RXRX
RXRX
Revenue
$63.5M
$35.5M
Net Profit
$22.1M
$-108.1M
Gross Margin
59.8%
Operating Margin
41.7%
-304.8%
Net Margin
34.8%
-304.2%
Revenue YoY
28.4%
681.7%
Net Profit YoY
30.0%
39.6%
EPS (diluted)
$1.07
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
EQBK
EQBK
RXRX
RXRX
Q4 25
$63.5M
$35.5M
Q3 25
$18.0M
$5.2M
Q2 25
$58.4M
$19.2M
Q1 25
$60.6M
$14.7M
Q4 24
$58.3M
$4.5M
Q3 24
$55.3M
$26.1M
Q2 24
$55.4M
$14.4M
Q1 24
$55.9M
$13.8M
Net Profit
EQBK
EQBK
RXRX
RXRX
Q4 25
$22.1M
$-108.1M
Q3 25
$-29.7M
$-162.3M
Q2 25
$15.3M
$-171.9M
Q1 25
$15.0M
$-202.5M
Q4 24
$17.0M
$-178.9M
Q3 24
$19.9M
$-95.8M
Q2 24
$11.7M
$-97.5M
Q1 24
$14.1M
$-91.4M
Gross Margin
EQBK
EQBK
RXRX
RXRX
Q4 25
59.8%
Q3 25
-183.8%
Q2 25
-4.9%
Q1 25
-48.0%
Q4 24
-181.4%
Q3 24
53.7%
Q2 24
36.2%
Q1 24
19.1%
Operating Margin
EQBK
EQBK
RXRX
RXRX
Q4 25
41.7%
-304.8%
Q3 25
-207.2%
-3327.6%
Q2 25
31.5%
-916.8%
Q1 25
31.1%
-1297.9%
Q4 24
35.0%
-4042.4%
Q3 24
43.1%
-377.1%
Q2 24
29.4%
-697.4%
Q1 24
31.8%
-698.4%
Net Margin
EQBK
EQBK
RXRX
RXRX
Q4 25
34.8%
-304.2%
Q3 25
-164.7%
-3135.3%
Q2 25
26.1%
-894.2%
Q1 25
24.8%
-1373.3%
Q4 24
29.1%
-3935.5%
Q3 24
35.9%
-367.5%
Q2 24
21.1%
-676.6%
Q1 24
25.2%
-662.4%
EPS (diluted)
EQBK
EQBK
RXRX
RXRX
Q4 25
$1.07
$-0.17
Q3 25
$-1.55
$-0.36
Q2 25
$0.86
$-0.41
Q1 25
$0.85
$-0.50
Q4 24
$1.06
$-0.56
Q3 24
$1.28
$-0.34
Q2 24
$0.76
$-0.40
Q1 24
$0.90
$-0.39

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
EQBK
EQBK
RXRX
RXRX
Cash + ST InvestmentsLiquidity on hand
$743.3M
Total DebtLower is stronger
$443.2M
$9.6M
Stockholders' EquityBook value
$732.1M
$1.1B
Total Assets
$6.4B
$1.5B
Debt / EquityLower = less leverage
0.61×
0.01×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
EQBK
EQBK
RXRX
RXRX
Q4 25
$743.3M
Q3 25
$659.8M
Q2 25
$525.1M
Q1 25
$500.5M
Q4 24
$594.4M
Q3 24
$427.6M
Q2 24
$474.3M
Q1 24
$296.3M
Total Debt
EQBK
EQBK
RXRX
RXRX
Q4 25
$443.2M
$9.6M
Q3 25
$486.9M
$11.9M
Q2 25
$448.4M
$14.2M
Q1 25
$376.9M
$16.4M
Q4 24
$312.8M
$19.0M
Q3 24
$437.5M
$20.5M
Q2 24
$391.7M
$22.9M
Q1 24
$367.1M
Stockholders' Equity
EQBK
EQBK
RXRX
RXRX
Q4 25
$732.1M
$1.1B
Q3 25
$711.9M
$1.0B
Q2 25
$635.6M
$919.1M
Q1 25
$617.3M
$933.9M
Q4 24
$592.9M
$1.0B
Q3 24
$504.0M
$524.6M
Q2 24
$461.4M
$584.4M
Q1 24
$456.8M
$401.2M
Total Assets
EQBK
EQBK
RXRX
RXRX
Q4 25
$6.4B
$1.5B
Q3 25
$6.4B
$1.4B
Q2 25
$5.4B
$1.3B
Q1 25
$5.4B
$1.3B
Q4 24
$5.3B
$1.4B
Q3 24
$5.4B
$726.5M
Q2 24
$5.2B
$775.9M
Q1 24
$5.2B
$557.8M
Debt / Equity
EQBK
EQBK
RXRX
RXRX
Q4 25
0.61×
0.01×
Q3 25
0.68×
0.01×
Q2 25
0.71×
0.02×
Q1 25
0.61×
0.02×
Q4 24
0.53×
0.02×
Q3 24
0.87×
0.04×
Q2 24
0.85×
0.04×
Q1 24
0.80×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
EQBK
EQBK
RXRX
RXRX
Operating Cash FlowLast quarter
$51.4M
$-46.1M
Free Cash FlowOCF − Capex
$38.1M
$-47.3M
FCF MarginFCF / Revenue
60.0%
-133.1%
Capex IntensityCapex / Revenue
20.9%
3.5%
Cash ConversionOCF / Net Profit
2.33×
TTM Free Cash FlowTrailing 4 quarters
$88.8M
$-378.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
EQBK
EQBK
RXRX
RXRX
Q4 25
$51.4M
$-46.1M
Q3 25
$8.5M
$-117.4M
Q2 25
$28.3M
$-76.4M
Q1 25
$21.7M
$-132.0M
Q4 24
$73.8M
$-115.4M
Q3 24
$23.5M
$-59.2M
Q2 24
$16.0M
$-82.2M
Q1 24
$12.6M
$-102.3M
Free Cash Flow
EQBK
EQBK
RXRX
RXRX
Q4 25
$38.1M
$-47.3M
Q3 25
$4.5M
$-117.6M
Q2 25
$26.0M
$-79.6M
Q1 25
$20.2M
$-133.8M
Q4 24
$65.4M
$-116.7M
Q3 24
$19.7M
$-63.8M
Q2 24
$15.2M
$-83.4M
Q1 24
$10.6M
$-109.0M
FCF Margin
EQBK
EQBK
RXRX
RXRX
Q4 25
60.0%
-133.1%
Q3 25
24.7%
-2272.5%
Q2 25
44.5%
-413.9%
Q1 25
33.3%
-907.4%
Q4 24
112.1%
-2567.7%
Q3 24
35.6%
-244.6%
Q2 24
27.4%
-578.5%
Q1 24
19.0%
-789.9%
Capex Intensity
EQBK
EQBK
RXRX
RXRX
Q4 25
20.9%
3.5%
Q3 25
22.3%
4.7%
Q2 25
3.9%
16.4%
Q1 25
2.4%
12.4%
Q4 24
14.6%
28.6%
Q3 24
6.8%
17.5%
Q2 24
1.5%
8.2%
Q1 24
3.6%
48.2%
Cash Conversion
EQBK
EQBK
RXRX
RXRX
Q4 25
2.33×
Q3 25
Q2 25
1.85×
Q1 25
1.44×
Q4 24
4.35×
Q3 24
1.18×
Q2 24
1.37×
Q1 24
0.90×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons